ConductScience.org, home

Paper31396148

Prospective Assessment of No Evidence of Disease Activity-4 Status in Early Disease Stages of Multiple Sclerosis in Routine Clinical Practice.

Guevara C and 11 others. Front Neurol, 2019. Cited by 15 papers, by iCite.

Cite this record

ConductScience Library. Prospective Assessment of No Evidence of Disease Activity-4 Status in Early Disease Stages of Multiple Sclerosis in Routine Clinical Practice. Papers, record 31396148. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/31396148

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Prospective Assessment of No Evidence of Disease Activity-4 Status in Early Disease Stages of Multiple Sclerosis in Routine Clinical Practice.
PubMed
Journal
Front Neurol
PubMed
Year
2019
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
15
iCite
Relative citation ratio, by iCite
0.81
iCite
Revised in PubMed
2020-10-01
PubMed

Authors12

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Guevara CCarlos
2Garrido CCristian
3Martinez MMelissa
4Farias GAGonzalo A
5Orellana PPatricia
6Soruco WWendy
7Alarcón PPablo
8Diaz VVioleta
9Silva CCarlos
10Kempton MJMatthew J
11Barker GGareth
12de Grazia JJosé

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References33

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
110506095The natural history of multiple sclerosis: a geographically based study. 7. Progressive-relapsing and relapsing-progressive multiple sclerosis: a re-evaluation.Brain1999https://conductscience.org/library/papers/10506095PubMed
211351200Normalized accurate measurement of longitudinal brain change.J Comput Assist Tomogr2001https://conductscience.org/library/papers/11351200PubMed
312372740Brain atrophy in mild or moderate traumatic brain injury: a longitudinal quantitative analysis.AJNR Am J Neuroradiol2002https://conductscience.org/library/papers/12372740PubMed
412482100Accurate, robust, and automated longitudinal and cross-sectional brain change analysis.Neuroimage2002https://conductscience.org/library/papers/12482100PubMed
515501092Advances in functional and structural MR image analysis and implementation as FSL.Neuroimage2004https://conductscience.org/library/papers/15501092PubMed
615911795Risk factors for progression of brain atrophy in aging: six-year follow-up of normal subjects.Neurology2005https://conductscience.org/library/papers/15911795PubMed
717178742Manifestations of early brain recovery associated with abstinence from alcoholism.Brain2007https://conductscience.org/library/papers/17178742PubMed
817940723Detecting treatment effects on brain atrophy in relapsing remitting multiple sclerosis: sample size estimates.J Neurol2007https://conductscience.org/library/papers/17940723PubMed
918064587Effects of acute dehydration on brain morphology in healthy humans.Hum Brain Mapp2009https://conductscience.org/library/papers/18064587PubMed
1019168190Gray matter atrophy and disability progression in patients with early relapsing-remitting multiple sclerosis: a 5-year longitudinal study.J Neurol Sci2009https://conductscience.org/library/papers/19168190PubMed
1120089952A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.N Engl J Med2010https://conductscience.org/library/papers/20089952PubMed
1220483380Evaluation of automated techniques for the quantification of grey matter atrophy in patients with multiple sclerosis.Neuroimage2010https://conductscience.org/library/papers/20483380PubMed
1321387374Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria.Ann Neurol2011https://conductscience.org/library/papers/21387374PubMed
142259435Towards quantitative measurements of relaxation times and other parameters in the brain.Neuroradiology1990https://conductscience.org/library/papers/2259435PubMed
1522799620Brief International Cognitive Assessment for MS (BICAMS): international standards for validation.BMC Neurol2012https://conductscience.org/library/papers/22799620PubMed
1623153407Measurement and clinical effect of grey matter pathology in multiple sclerosis.Lancet Neurol2012https://conductscience.org/library/papers/23153407PubMed
1724446248Clinical relevance of brain volume measures in multiple sclerosis.CNS Drugs2014https://conductscience.org/library/papers/24446248PubMed
1825531931Evaluation of no evidence of disease activity in a 7-year longitudinal multiple sclerosis cohort.JAMA Neurol2015https://conductscience.org/library/papers/25531931PubMed
1925877624Editors' welcome and a working definition for a multiple sclerosis cure.Mult Scler Relat Disord2013https://conductscience.org/library/papers/25877624PubMed
2025904813Establishing pathological cut-offs of brain atrophy rates in multiple sclerosis.J Neurol Neurosurg Psychiatry2016https://conductscience.org/library/papers/25904813PubMed

See all 33 referencesDownload CSV of references

Cited by9

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 15 citations.

PMIDTitleJournalYearIn PapersSource
39379875Brain volume loss in relapsing multiple sclerosis: indirect treatment comparisons of available disease-modifying therapies.BMC Neurol2024https://conductscience.org/library/papers/39379875PubMed
39251843Assessing disease progression and treatment response in progressive multiple sclerosis.Nat Rev Neurol2024https://conductscience.org/library/papers/39251843PubMed
38347079Efficacy and safety of rituximab in multiple sclerosis and neuromyelitis optica spectrum disorder.Sci Rep2024https://conductscience.org/library/papers/38347079PubMed
37864717Identification and management of subclinical disease activity in early multiple sclerosis: a review.J Neurol2024https://conductscience.org/library/papers/37864717PubMed
37819598No Evidence of Disease Activity (NEDA) as a Clinical Assessment Tool for Multiple Sclerosis: Clinician and Patient Perspectives [Narrative Review].Neurol Ther2023https://conductscience.org/library/papers/37819598PubMed
37448960Magnetic resonance imaging and ultrasound elastography in the context of preclinical pharmacological research: significance for the 3R principles.Front Pharmacol2023https://conductscience.org/library/papers/37448960PubMed
36901807Recent Progress in the Identification of Early Transition Biomarkers from Relapsing-Remitting to Progressive Multiple Sclerosis.Int J Mol Sci2023https://conductscience.org/library/papers/36901807PubMed
36114980Unmet needs and gaps in the identification of secondary progression in multiple sclerosis: a Southern Italy healthcare professionals' perspective.Neurol Sci2023https://conductscience.org/library/papers/36114980PubMed
35159972Brain Volume Loss Can Occur at the Rate of Normal Aging in Patients with Multiple Sclerosis Who Are Free from Disease Activity.J Clin Med2022https://conductscience.org/library/papers/35159972PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/31396148

GET https://conductscience.org/api/papers/v1/31396148/references?page=2